Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients.
Gordon GoodallMark LamotteMafalda RamosFranck MaunouryBarbora PejchalovaGerard de PouvourvillePublished in: Journal of medical economics (2019)
In our analyses of intermediate risk patients, TAVI is associated with superior clinical outcomes compared to surgery and is cost saving. It could be expected that cost savings are conservative and likely to increase over time.
Keyphrases
- end stage renal disease
- ejection fraction
- aortic valve
- newly diagnosed
- transcatheter aortic valve replacement
- minimally invasive
- chronic kidney disease
- transcatheter aortic valve implantation
- aortic stenosis
- prognostic factors
- heart failure
- coronary artery bypass
- patient reported outcomes
- coronary artery disease
- left ventricular
- patient reported